ITM0354
ITM0354
- Catalog: ITM0354
- Gene/Protein: IFNG
- Product Description: Immunotag™ IFN-γ Monoclonal Antibody
504.0000
Price in reward points: 504
| Antibody Specification | |
| Datasheet | 
|
| Target Protein | IFN-γ |
| Clonality | Monoclonal |
| Storage/Stability | -20°C/1 year |
| Application | WB,ELISA |
| Recommended Dilution | Western Blot: 1/500 - 1/2000. ELISA: 1/10000. Not yet tested in other applications. |
| Concentration | 1 mg/ml |
| Reactive Species | Human |
| Host Species | Mouse |
| Immunogen | Recombinant human IFN-γ (BioSource company, Cat.No. PHC4033) |
| Specificity | IFN-γ Monoclonal Antibody detects endogenous levels of IFN-γ protein. |
| Purification | Affinity purification |
| Form | Purified antibody in PBS containing 0.03% sodium azide. |
| Gene Name | IFNG |
| Accession No. | P01579 P01580 |
| Alternate Names | IFNG; Interferon gamma; IFN-gamma; Immune interferon |
| Description | interferon gamma(IFNG) Homo sapiens This gene encodes a soluble cytokine that is a member of the type II interferon class. The encoded protein is secreted by cells of both the innate and adaptive immune systems. The active protein is a homodimer that binds to the interferon gamma receptor which triggers a cellular response to viral and microbial infections. Mutations in this gene are associated with an increased susceptibility to viral, bacterial and parasitic infections and to several autoimmune diseases. [provided by RefSeq, Dec 2015], |
| Cell Pathway/ Category | Proteasome,Cytokine-cytokine receptor interaction,Regulation of autophagy,TGF-beta,Jak_STAT,Natural killer cell mediated cytotoxicity,T_Cell_Receptor,Type I diabetes mellitus,Systemic lupus erythematosus,Allograft rejection,Graft-versus-host disease, |
| Protein Expression | Blood, |
| Subcellular Localization | extracellular region,extracellular space,cytoplasm,external side of plasma membrane,neuron projection,perikaryon, |
| Protein Function | disease:In Caucasians, genetic variation in IFNG is associated with the risk of aplastic anemia (AA) [MIM:609135]. AA is a rare disease in which the reduction of the circulating blood cells results from damage to the stem cell pool in bone marrow. In most patients, the stem cell lesion is caused by an autoimmune attack. T-lymphocytes, activated by an endogenous or exogenous, and most often unknown antigenic stimulus, secrete cytokines, including IFN-gamma, which would in turn be able to suppress hematopoiesis.,function:Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons.,online information:Interferon gamma entry,pharmaceutical:Available under the name Actimmune (Genentech). Used for reducing the frequency and severity of serious infections associated with chronic granulomatous disease (CGD).,PTM:Proteolytic processing produces C-terminal heterogeneity, with proteins ending alternatively at Gly-150, Met-157 or Gly-161.,similarity:Belongs to the type II (or gamma) interferon family.,subunit:Homodimer.,tissue specificity:Released primarily from activated T lymphocytes., |
| Usage | For Research Use Only! Not for diagnostic or therapeutic procedures. |
| Material Safety Data Sheet | |
| English_US |
|
| Danish |
|
| Dutch |
|
| English_UK |
|
| French |
|
| German |
|
| Spanish |
|
| Norwegian |
|
| Portuguese |
|
| Finnish |
|
| Swedish |
|
| Polish |
|